• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 7, 2016

View Archived Issues

Abides by SAMURAI, heartened for SPARTAN: No pain for Colucid on phase III migraine data

A slightly higher-than-previous placebo response on the primary endpoint of two hours' freedom from headache did little to take the shine off top-line phase III migraine data disclosed by Colucid Pharmaceuticals Inc. with lasmiditan tablets in the trial known as SAMURAI. Read More

GSK touts real-world data for COPD drug in Salford lung study

LONDON – Glaxosmithkline plc has reported statistically significant results in what it claims is the world's first real-world randomized control trial, the Salford lung study (SLS). Read More

Astrazeneca looks to benralizumab as next-gen asthma standout

Looking to mine more gold from its respiratory drug franchise, Astrazeneca plc offered up full data from the pivotal phase III trials of benralizumab at the European Respiratory Society (ERS) meeting in London, seeking to position the company's first biologic respiratory medicine as a key differentiator in the space. Read More

Final closing takes Rigontec's series A financing to $33M

DUBLIN – A syndicate of European venture capital investors has followed its own money in a sizable third closing of Rigontec GmbH's series A round, adding €15 million (US$16.7 million) in new cash, which takes the final tally to €29.25 million. Read More

Japan's Takeda wins Zika funding from BARDA; initial $19.8M

TOKYO – Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, will attempt to develop a vaccine to tackle the Zika virus with funding from the U.S. government worth up to $311 million. Read More

DBV extending allergy patch technology into vaccine development

DUBLIN – DBV Technologies SA is extending its patch-based antigen delivery technology, which is currently undergoing a pivotal phase III trial in a food allergy indication, into its first vaccine study. Read More

Gene diversity can alter metabolic individuality

HONG KONG – A new Japanese study of the effects of environmental and genetic influences on individual differences in proteomics and metabolomics has identified biomarkers for early disease prevention and diagnosis, through the identification and quantification of blood metabolites. Read More

FDA: Celator's ASCO exhibit stepped over the OPDP line

In its third letter of the year, the FDA's Office of Prescription Drug Promotion (OPDP) came down on Celator Pharmaceuticals Inc. for promoting a promising but yet-to-be-approved cancer drug in an exhibit at the American Society for Clinical Oncology's (ASCO) annual meeting in June. Read More

Financings

C4X Discovery Holdings plc, of Manchester, U.K., raised £5 million (US$6.7 million) by placing approximately 4.9 million ordinary shares with current and new investors at 102 pence apiece. Read More

Other news to note

Spero Therapeutics LLC, of Cambridge, Mass., joined the ENABLE (European Gram-Negative Antibacterial Engine) project, which focuses on the development of promising early stage antimicrobial candidates to treat gram-negative infections. Read More

In the clinic

Basilea Pharmaceutica Ltd., of Basel, Switzerland, said the first patient was dosed in a phase I/IIa continuous infusion study with its tumor checkpoint controller, BAL101553, in patients with advanced solid cancers. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe